Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00501
|
|||||
| Drug Name |
Desipramine
|
|||||
| Synonyms |
(3-(10H,11H-Dibenzo[b,f]azepin-5-yl)propyl)methylamine; 10, 11-Dihydro-N-methyl-5H-dibez[b,f]azepine-5-propanamine; 10,11-Dihydro-5-(3-methylaminopropyl)-5H-dibenz(b,f)azepine; 3-(10,11-DIHYDRO-5H-DIBENZO[B,F]AZEPIN-5-YL)-N-METHYLPROPAN-1-AMINE; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine; 5-(gamma-Methylaminopropyl)iminodibenzyl; DMI (pharmaceutical); DMI 50475; Demethylimipramine; Desimipramine; Desimpramine; Desipramin; Desipramina; Desipramina [INN-Spanish]; Desipramine (D4); Desipramine (INN); Desipramine Hcl; Desipramine [INN:BAN]; Desipraminum; Desipraminum [INN-Latin]; Desmethylimipramine; Dezipramine; Dimethylimipramine; Methylaminopropyliminodibenzyl; Monodemethylimipramine; N-(3-Methylaminopropyl)iminobibenzyl; Norimipramine; Norpramin (TN); Norpramine; Pentofran; Pertofrane (TN); Pertrofane; Sertofran; ZERO/006017
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Attention deficit hyperactivity disorder [ICD11:6A05] | Approved | [1] | |||
| Depression [ICD11:6A8Z] | Approved | [1] | ||||
| Therapeutic Class |
Antidepressants
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C18H22N2
|
|||||
| Canonical SMILES |
CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31
|
|||||
| InChI |
InChI=1S/C18H22N2/c1-19-13-6-14-20-17-9-4-2-7-15(17)11-12-16-8-3-5-10-18(16)20/h2-5,7-10,19H,6,11-14H2,1H3
|
|||||
| InChIKey |
HCYAFALTSJYZDH-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 50-47-5
|
|||||
| Pharmaceutical Properties | Molecular Weight | 266.4 | Topological Polar Surface Area | 15.3 | ||
| Heavy Atom Count | 20 | Rotatable Bond Count | 4 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 2 | |||
| XLogP |
4.9
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10524411
,11111066
,11111067
,11335365
,11360604
,11363335
,11365897
,11368459
,11371457
,11374067
,11376621
,11461576
,11466371
,11467491
,11483778
,11486062
,11487907
,11490195
,11492129
,11494255
,14774838
,29214812
,29222144
,3249345
,3727070
,46504624
,47291013
,47291014
,47736341
,47736342
,47736343
,47959596
,48259094
,48259095
,48415856
,49698852
,49961473
,50100220
,50104283
,5321893
,53787179
,57321547
,647048
,76076257
,7737258
,7979043
,8151907
,85209781
,85753308
,9158
|
|||||
| ChEBI ID |
ChEBI:47781
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | 1-Oct | Transporter Info | Organic cation transporter 1 | Substrate | [2] | |
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [3] | ||
| References | ||||||
| 1 | Desipramine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33. | |||||
| 3 | A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.